TCT-595 Location of Side Branch Access Critically Affects Results in Bifurcation Stenting: Insights From In-vitro Modeling and Optical Coherence Tomography  by Foin, Nicolas et al.
TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM www.jacctctabstracts2013.com
P
O
S
T
E
R
SSanta Clara, USA) in the treatment of 101 patients with de novo native coronary artery
lesions. The current analysis included 51 patients with 143 OCT pullbacks (Baseline:
52, 6 month: 25, 1 year: 22, 2 year: 26, 3 year: 18) who underwent OCT at baseline
and follow-up. The presence of acute disruption or late discontinuities was diagnosed
by the presence on OCT of stacked, overhung struts or isolated intraluminal struts
disconnected from the expected circularity of the device.
Results: Out of 51 patients with OCT imaging post-procedure, acute scaffold
disruption was observed in 2 patients (3.9%). One patient had a target lesion revas-
cularization presumably related to the disruption. Out of 49 patients without acute
disruption, late discontinuities were observed in 21 patients. There were no major
adverse cardiac events associated with this ﬁnding except for one patient who had
a non-ischemia driven target lesion revascularization.
Conclusions: Acute scaffold disruption is a rare iatrogenic phenomenon that has been
anecdotally associated with anginal symptoms, whereas late strut discontinuity is
observed in approximately 40% of patients and could be viewed as a serendipitous
OCT ﬁnding of a normal bioresorption process without clinical implications.
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Background: During the ﬁrst 3 years after implantation of an everolimus-eluting
poly-l-lactic-acid (PLLA) scaffold (Absorb BVS, Abbott Vascular), the polymeric
struts are progressively hydrolyzed and subsequently replaced by proteoglycan.
Eventually, the provisional matrix becomes cellularized by smooth　muscle cell or
connective tissue. Previous preclinical studies demonstrated that Optical Coherence
Tomography (OCT) by visual assessment is unable to distinguish polylactide from
proteoglycan, and therefore is not sensitive enough to investigate the process of
bioresorption. Light intensity assessment of strut on OCT might be a sophisticated
method to quantify the phenomenon of cellularization. The aim of this study was to
test this novel quantitative method on serial human OCT.
Methods: In the ABSORB Cohort B2 trial, 17 patients underwent serial frequency-
domain OCT post procedure, at 1year and at 3 years. Corresponding struts in corre-
sponding cross-sections at different times were detected by using anatomical land-
marks. The region of interest (ROI) encompassing the corresponding struts was
selected visually; two different intensity assessments were performed: one was "Area
assessment" for measuring the mean intensity value of the strut area line and the other
was "Line assessment" for measuring the peak intensity value along a single scan line.
Results: A total of 172 corresponding struts were sequentially analyzed. The results
are shown in the table. (Figure)Conclusions: The mean and peak light intensity of corresponding struts increased
steadily from baseline to 3 years, suggesting that this quantitative method of OCT
assessment might be valuable for monitoring the resorption process of polymeric
bioresorbable scaffolds.B180 JACC Vol 62/18/Suppl B j October 27–NoveTCT-594
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Background: Different stent material/design and post-dilatation strategies can impact
on ﬁnal stent expansion. The aim of this study was to evaluate the acute recoil of the
latest-generation coronary stents compared with conventional stents.
Methods: Optical coherence tomography (OCT) imaging was performed on 3 latest-
generation (LG) stents (Multi-Link 8, Integrity and Element), 2 conventional cobalt
chromium (CC) stents (Driver and Vision) and 3 conventional stainless steel (SS)
stents (Select, Liberté and S-Stent) (F3.0 mm, N¼6 each) during and after balloon
inﬂation in a silicone-tube bench model. After nominal-pressure deployment (15 sec),
a single long (30 sec) vs. multiple short (10 sec x 3 times) post-dilatations were
performed using a non-compliant balloon (3.25 mm, 20 atm).
Results: Stent areas during deployment signiﬁcantly varied among 3 groups (LG 6.5,
CC 7.1, SS 6.1 mm2, p<0.01). Recoil after deﬂation in LG was similar to SS, but
smaller than CC (-8.1%, -8.2%, -12.1%, p<0.01). Signiﬁcant recoil was also observed
after post-dilatation, regardless of stent types and inﬂation strategies. Overall, multiple
short inﬂations achieved greater ﬁnal stent areas than single long inﬂation (Figure).
Final stent area in LG was similar to CC, but smaller than SS (7.5, 7.5, 7.9 mm2,
p<0.01). In the LG group, these results were not different among 3 stent types.Conclusions: Real-time OCT revealed signiﬁcant acute recoil in the latest-generation
stents as well as conventional stents. For post-dilatation, multiple short inﬂations may
be better than single long inﬂation in optimizing the ﬁnal stent expansion.
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Background: The aim of this study was to evaluate the impact of stent design and
side branch access on ﬁnal strut apposition during bifurcation stenting.
Methods: 42 samples of 6 different commercially available Drug Eluting Stents
(DES) were deployed in an identical in-vitro coronary bifurcation model. The platform
tested were 16mm to 28mm in length and included the Everolimus eluting Xience V
(n¼9, Abbott Vascular, Santa Clara, CA), Promus Element (n¼9, Boston Scientiﬁc,
Natick, MA), the Paclitaxel eluting Taxus Liberte (n¼8, Boston Scientiﬁc, Natick,
MA), the Biolimus eluting Biomatrix Flex (n¼7, Biosensors International, Morges,
Switzerland), the Sirolimus eluting Cypher Select (n¼4, Cordis, Warren, NJ) and the
Zotaroliums eluting Resolute stents (n¼5), Medtronic, Santa Rosa, CA). Kissing
Balloon (KB) optimization was performed after either a proximal or a distal recrossing
of the guidewire and results were analyzed by Micro Computed-Tomography.
Results:When theSideBranch (SB)was accessed through amid-distal cell, average rates
of strut malapposition observed inside the bifurcation conﬂuence area remained low with
no signiﬁcant differences observed between the different platforms tested [15.4%-23.6%].
Conversely, proximal instead of distal cell recrossing toward the side branch producedmber 1, 2013 j TCT Abstracts/POSTER/Intravascular Imaging and PCI
Parameter
ST-Exp
70%(n=672)
ST-Exp 60-
70%(n=159)
ST-Exp
<60%(n=58) p-value
ST-Exp (%) 82.1 [76.7,
86.7]
65.8 [63.7,
68.0]
55.0 [51.4,
57.4]
<0.0001
MSA (mm2) 6.5 [5.0, 8.2] 5.2 [4.1, 6.5] 4.1 [3.2, 4.9] <0.0001
Lesion length
(mm)
21.0 [15.4,
30.2]
32.1 [22.2,
46.7]
47.5 [32.8,
62.0]
<0.0001
Plaque burden
at MLA (%)
77.6 [69.2,
83.7]
77.7 [69.5,
83.9]
80.3 [75.2,
85.2]
0.18
Superﬁcial arc
of calcium ()
87 [47, 145] 100 [68, 171] 159 [90, 230] <0.0001
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Sa signiﬁcant higher rates of malapposed strut, particularly toward the SB ostium (40.6 
6.0%versus 26.0 5.7%, p¼0.0005), aswell as a higher SB lumen residual stenosis than
after mid-distal recrossing (39.7  7.1 % versus 18.9  8.0 %, p < 0.0001). In-vivo
Optical Coherence Tomography (OCT) analysis on 52 patients undergoing elective
treatment of bifurcation lesions using provisional stenting showed that using OCT to
guide cell recrossing is feasible and can reduce signiﬁcantly strut malapposition in
bifurcation. Patients who were treated using OCT-guided distal recrossing had a signiﬁ-
cantly lower number of malapposed stent struts, especially in the quadrants towards the
SB ostium than in the angiography-guided group (9.5% vs 42.3%, p<0.0001).
Conclusions: Optimal distal cell recrossing of the guidewire is critical to ensure
a successful stent optimization in bifurcation PCI.
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Background: The DESolve Bioresorbable Scaffold is a novel drug-eluting device
combining a PLLA-based scaffold coated with a bioresorbable polylactide-based
polymer and a potent anti-proliferative sirolimus metabolite, Novolimus. The drug dose
is 5 mcg per mm of scaffold length. An early beneﬁt with regard to vessel restoration is
a potential feature of this unique technology. The aim of this study is to assess the serial
changes in the vessel treated with the DESolve scaffold using IVUS technology.
Methods: The DESolve NX is a pivotal, prospective and multicentre clinical trial, which
enrolled 126 patients with de novo coronary lesions treated with a single scaffold
available in three diameters (3.0, 3.25 and 3.5) and two lengths (14 and 18 mm). The ﬁrst
46 patients enrolled in this trial were part of an IVUS sub-study, which consisted of
a paired analysis of the automatic pullbacks performed at the end of the baseline
procedure and at six-month follow-up (an additional 24 month follow up will also be
performed). All analyses are being performed by an independent IVUS core lab.
Results: The mean age of the study population was 62 years, 68% of which were men
and 21% had diabetes. Pre procedure reference vessel lesion length and diameter were
11.2  3.8mm and 3.06  0.31, respectively. 40 of the 46 patients enrolled in the
IVUS sub study had serial analyses available at 6 months that demonstrated
a signiﬁcant increase in mean lumen (D 9.0%, p ¼ <0.001), scaffold (D 15.7%,
p ¼ <0.001) and vessel (D 16.8 %, p ¼ <0.001) areas between baseline and 6 months
and low % volume obstruction (5.05%) with no case of late acquired scaffold
incomplete apposition or aneurysm formation.
Conclusions: The DESolve scaffold is the ﬁrst scaffold to demonstrate lumen area
enlargement with no chronic recoil at 6 month follow up with no evidence of aneu-
rysms. Serial IVUS results at 6 months showed effective neointimal suppression and
no late acquired strut malapposition suggesting the natural ability of the scaffolded
vessel to remodel at 6 months.
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Background: While a smaller minimum stent cross-sectional area (MSA) predicts
adverse events (stent restenosis and thrombosis), predictors of stent underexpansion
have not been fully investigated.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrMethods: ADAPT-DES was a prospective, multicenter, registry of 8,583 consecutive
pts with undergoing PCI with DES. Among 2064 pts enrolled in a pre-speciﬁed
intravascular ultrasound (IVUS) substudy, 769 pts with 889 lesions were examined by
both pre and post-PCI IVUS. Stent expansion (ST-Exp) was calculated as MSA
divided by average of proximal and distal stent edge lumen area; %ST-Exp was
divided into (1) 70% (adequate expansion), (2) 60-70% (moderate underexpansion),
and (3) <60% (severe underexpansion).
Results: Lesion length was longer and maximum arc of superﬁcial calcium was
greater in the severe underexpansion group than in the other 2 groups (Table). These
ﬁndings were independent of vessel size and were also similar when stent expansion
was divided into tertiles: highest tertile of stent expansion (ST-exp >83%), middle
tertile (73%-83%), and lowest tertiles (ST-exp <73%). Multiple logistic regression
analysis revealed that lesion length [OR 1.80 per 10 mm (1.54, 2.09), p<0.0001] and
maximum arc of superﬁcial calcium [OR 1.13 per 90 (1.30, 2.00), p¼0.006] were
independently associated with severe stent underexpansion (ST-Exp<60%). ROC
curve analysis showed that cut-off values of lesion length and maximum arc of
superﬁcial calcium that best predicted stent expansion <60% (severe underexpansion)
were 42.0 mm and 127. Conversely, plaque burden was unrelated to stent expansion.
Conclusions: Lesion length and the extent of superﬁcial calcium are the strongest
determinants of stent underexpansion.TCT-598
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Background: Incomplete stent apposition (ISA) is a potential factor in the subsequent
development of later adverse events, including stent thrombosis, in patients treated
with drug-eluting stents (DES). We assessed the incidence and mechanisms of ISA in
patients with ST-segment Elevation Myocardial Infarction (STEMI) treated with
a biolimus-eluting Nobori stent (BES) or a sirolimus-eluting Cypher stent (SES).
Methods: In the Randomized Comparison of Biolimus-Eluting Biodegradable Poly-
mer Coated Stent and Durable Polymer Sirolimus-Eluting Stent in Unselected Patients
(SORT OUT V) trial, a prespeciﬁed intravascular ultrasound (IVUS) substudy
enrolled 116 STEMI patients (57 BESs and 59 SESs) treated with PPCI where post-
procedure and 12-month follow-up imaging data were available. The vascular
response and inﬂuence of remodeling (changes in external elastic membrane (EEM)
cross sectional area (CSA)) in “acute”, “resolved”, and “late acquired” ISA was
evaluated.
Results: Post-intervention ISA occurred in 22 (19.0%) stented lesions (15.8% BES
and 22.0% SES, p¼ns). Of these, 7 (31.8%) resolved at follow-up without signiﬁcant
remodeling (post-intervention EEM CSA 19.7 mm2 (interquartile range (IQR) 17.0 to
23.5 mm2) vs. follow-up EEM CSA 20.9 mm2 IQR 17.8 to 23.5 mm2), p¼ns. Plaque
CSA increased from post-intervention 6.7 mm2 (IQR 5.5 to 8.9 mm2) to follow-up
plaque CSA 10.0 mm2 (IQR 9.2 to 12.4 mm2), p¼0.018. At follow-up late acquired
ISA was seen in 19 (16.4%) stented lesions (14.0% BES and 18.6% SES, p¼ns). In
patients with late acquired ISA, the mechanism was positive remodeling in 73.7% of
the stented lesions (post-intervention EEM CSA 21.0 mm2 (IQR 13.5 to 26.9 mm2)
vs. follow-up EEM CSA 27.4 mm2 (IQR 18.6 to 31.3 mm2), p¼0.001, and maximum
ISA CSA was 3.5 mm2 (IQR 1.3 to 5.8 mm2). In 26.3% of the patients with late
acquired ISA, negative remodeling and plaque/thrombus resolution was seen.
Conclusions: In STEMI patients "acute" ISA resolved in one third of the stented
lesions, mainly due to plaque progression. "Late acquired" ISA was predominantly
due to positive remodeling.acts/POSTER/Intravascular Imaging and PCI B181
